Omalizumab Injection [Xolair]
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder, Atopy
Trial Timeline
Jan 1, 2021 → Jan 1, 2022
NCT ID
NCT04535817About Omalizumab Injection [Xolair]
Omalizumab Injection [Xolair] is a phase 1 stage product being developed by Novartis for Autism Spectrum Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04535817. Target conditions include Autism Spectrum Disorder, Atopy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04535817 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Autism Spectrum Disorder